Custom Oligos
Total Trials
10
As Lead Sponsor
9
As Collaborator
1
Total Enrollment
4,802
NCT01583361
SOX Regimen as Neoadjuvant Chemotherapy for AJCC Stage II-III Gastric Cancer
Phase: Phase 3
Role: Lead Sponsor
Start: Mar 31, 2012
Completion: Jan 31, 2017
NCT05334849
Prospectively Predict the Immunotherapy Response of Gastric Cancer Based on Circulating Exosomal LncRNA-GC1 Biopsy
Phase: N/A
Start: Nov 1, 2018
Completion: Sep 30, 2022
NCT06390748
Esmolol in Sepsis Management:Evaluating Immunomodulatory Effects and Impact on Patient Outcomes
Phase: Phase 2
Start: Jan 1, 2021
Completion: Dec 31, 2023
NCT05397548
Use of Circulating Exosomal LncRNA-GC1 to Monitor Gastric Cancer
Start: May 1, 2022
NCT06379568
Risk of Aspergillus Infection in Patients With Chronic Lung Disease
Start: Jul 1, 2022
Completion: Jan 31, 2024
NCT06333379
Aspergillosis Detection Via EBC-GM in Ventilated Patients
Start: Jan 2, 2023
Completion: Jan 10, 2024
NCT06284746
Tirelizumab Combined With Chemotherapy in the Treatment of HER-2 Negative Locally Advanced Gastric Cancer
Start: Oct 1, 2023
Completion: Jul 30, 2025
NCT05890404
SGM Evidenced-Based Mental Healthcare Implementation
Role: Collaborator
Start: Feb 8, 2024
Completion: Jun 30, 2028
NCT06493448
Prospective Observational Cohort Study
Start: Jul 15, 2024
Completion: Dec 31, 2028
Loading map...